Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 14/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 14/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19496893 | 0.83 | TAS1R3 (0.41) | ADORA3ADORA2AADORA2BADORA1TAS1R3 | |
| SCHEMBL562820 | 0.82 | ADORA3 (0.46) | ADORA3ADORA2AADORA2BADORA1TAS1R3 | |
| SCHEMBL2834465 | 0.77 | ADORA3 (0.61) | ADORA3ADORA2AADORA2BADORA1TAS1R3 | |
| SCHEMBL1420530 | 0.73 | ADORA3 (0.57) | ADORA3ADORA2AADORA2BADORA1TAS1R3 | |
| SCHEMBL13753935 | 0.73 | ADORA3 (0.65) | ADORA3ADORA2AADORA2BADORA1TAS1R3 | |
| SCHEMBL562187 | 0.72 | ADORA3 (0.41) | ADORA3ADORA2AADORA2BADORA1TAS1R3 | |
| SCHEMBL19497015 | 0.72 | TAS1R3 (0.40) | ADORA3ADORA2AADORA2BADORA1TAS1R3 | |
| SCHEMBL4021787 | 0.72 | ADORA3 (0.68) | ADORA3ADORA2AADORA2BADORA1TAS1R3 | |
| SCHEMBL13248219 | 0.71 | ADORA3 (0.55) | ADORA3ADORA2AADORA2BADORA1TAS1R3 | |
| SCHEMBL13081990 | 0.71 | ADORA3 (0.62) | ADORA3ADORA2AADORA2BADORA1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2154970-B1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-8642633-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130137733-A1 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8404682-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2012-02-09 | — | — | US | disclosed |
| US-8013003-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | disclosed |
| EP-2154970-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008143963-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN2A, GRIN2B, SLC18A2 | ADORA3 140/4885ADORA2A 110/4885ADORA2B 122/4885 |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | DRD2, DRD3, GAP43 | ADORA3 284/4885ADORA2A 396/4885ADORA2B 810/4885 |
| US-20130137733-A1 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses | DRD2, DRD3, GAP43 | ADORA3 284/4885ADORA2A 396/4885ADORA2B 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.